Assessing the stability of polio eradication after the withdrawal of oral polio vaccine

The oral polio vaccine (OPV) contains live-attenuated polioviruses that induce immunity by causing low virulence infections in vaccine recipients and their close contacts. Widespread immunization with OPV has reduced the annual global burden of paralytic poliomyelitis by a factor of 10,000 or more and has driven wild poliovirus (WPV) to the brink of eradication. However, in instances that have so far been rare, OPV can paralyze vaccine recipients and generate vaccine-derived polio outbreaks. To complete polio eradication, OPV use should eventually cease, but doing so will leave a growing population fully susceptible to infection. If poliovirus is reintroduced after OPV cessation, under what conditions will OPV vaccination be required to interrupt transmission? Can conditions exist in which OPV and WPV reintroduction present similar risks of transmission? To answer these questions, we built a multi-scale mathematical model of infection and transmission calibrated to data from clinical trials and field epidemiology studies. At the within-host level, the model describes the effects of vaccination and waning immunity on shedding and oral susceptibility to infection. At the between-host level, the model emulates the interaction of shedding and oral susceptibility with sanitation and person-to-person contact patterns to determine the transmission rate in communities. Our results show that inactivated polio vaccine (IPV) is sufficient to prevent outbreaks in low transmission rate settings and that OPV can be reintroduced and withdrawn as needed in moderate transmission rate settings. However, in high transmission rate settings, the conditions that support vaccine-derived outbreaks have only been rare because population immunity has been high. Absent population immunity, the Sabin strains from OPV will be nearly as capable of causing outbreaks as WPV. If post-cessation outbreak responses are followed by new vaccine-derived outbreaks, strategies to restore population immunity will be required to ensure the stability of polio eradication.

[1]  R. Sutter,et al.  49 – Poliovirus Vaccine–Live , 2018 .

[2]  M. Rennels,et al.  Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. , 2005, The Journal of infectious diseases.

[3]  W. P. Glezen,et al.  Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. , 1969, American journal of epidemiology.

[4]  A A Tsiatis,et al.  Human infective dose determinations for oral poliovirus type 1 vaccine in infants , 1981, Journal of clinical microbiology.

[5]  John Tj,et al.  Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status , 2013 .

[6]  G. Dick,et al.  Vaccination Against Poliomyelitis with Live Virus Vaccines—8 , 1961, British medical journal.

[7]  M. Pallansch,et al.  Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination , 2015, BMC Infectious Diseases.

[8]  E. C. Beuvery,et al.  Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus. , 1999, Vaccine.

[9]  J. Fox,et al.  Intrafamilial and interfamilial spread of living vaccine strains of polioviruses. , 1959, Journal of the American Medical Association.

[10]  V. Agol,et al.  Retrospective Analysis of a Local Cessation of Vaccination against Poliomyelitis: a Possible Scenario for the Future , 2003, Journal of Virology.

[11]  J. Whalen,et al.  Transmission of polioviruses. III. Prevalence of polioviruses in pharyngeal secretions of infected household contacts of patients with clinical disease. , 1961, Pediatrics.

[12]  N Woodford,et al.  Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  R. Bassal,et al.  Field study of fecal excretion as a decision support tool in response to silent reintroduction of wild-type poliovirus 1 into Israel. , 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[14]  B. Hersh,et al.  Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988-1995. , 1997, The Journal of infectious diseases.

[15]  M. Zemlin,et al.  Ontogeny of the intestinal immune system , 2009 .

[16]  J. S. Reeves,et al.  Immunization of infants with the Sabin oral poliovirus vaccine. , 1962, American journal of public health and the nation's health.

[17]  R. Andino,et al.  Rationalizing the development of live attenuated virus vaccines , 2010, Nature Biotechnology.

[18]  Epidemiology Subcommittee Evaluation of Sabin live poliovirus vaccine in Japan. II. Clinical, virologic and immunologic effects of vaccine in children. , 1966, Japanese journal of medical science & biology.

[19]  N. Grassly,et al.  Efficacy of inactivated poliovirus vaccine in India , 2014, Science.

[20]  S. Cochi,et al.  Contribution of Global Polio Eradication Initiative–Funded Personnel to the Strengthening of Routine Immunization Programs in the 10 Focus Countries of the Polio Eradication and Endgame Strategic Plan , 2017, The Journal of infectious diseases.

[21]  M. Pallansch,et al.  Assessing population immunity in a persistently high-risk area for wild poliovirus transmission in India: a serological study in Moradabad, Western Uttar Pradesh. , 2014, The Journal of infectious diseases.

[22]  M. Pallansch,et al.  Expert Review on Poliovirus Immunity and Transmission , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[23]  J. Fox,et al.  Observations on natural poliovirus infections in immunized children. , 1957, American Journal of Public Health and the Nations Health.

[24]  Y. Manor,et al.  Insidious reintroduction of wild poliovirus into Israel, 2013. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[25]  Philip A. Eckhoff,et al.  Quantifying the Impact of Expanded Age Group Campaigns for Polio Eradication , 2014, PloS one.

[26]  A. Sasaki,et al.  Estimating the Risk of Re-Emergence after Stopping Polio Vaccination , 2012, Front. Microbio..

[27]  M. Kretzschmar,et al.  Linking the seroresponse to infection to within-host heterogeneity in antibody production. , 2016, Epidemics.

[28]  R. Sutter,et al.  Update on Vaccine-Derived Polioviruses — Worldwide, January 2017–June 2018 , 2016, MMWR. Morbidity and mortality weekly report.

[29]  Manfred S. Green,et al.  Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel. , 2008, Vaccine.

[30]  Hil M. Lyons,et al.  Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates. , 2017, Vaccine.

[31]  A. E. Casey THE INCUBATION PERIOD IN EPIDEMIC POLIOMYELITIS , 1942 .

[32]  R B Cairns,et al.  Friendships and social networks in childhood and adolescence: fluidity, reliability, and interrelations. , 1995, Child development.

[33]  A. Beale,et al.  A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine , 1966, Journal of Hygiene.

[34]  M. Famulare Has Wild Poliovirus Been Eliminated from Nigeria? , 2015, PloS one.

[35]  Roland W Sutter,et al.  The new polio eradication end game: rationale and supporting evidence. , 2014, The Journal of infectious diseases.

[36]  N. Nathanson,et al.  From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed , 2010, American journal of epidemiology.

[37]  E. Wimmer,et al.  Vaccination against polio should not be stopped , 2007, Nature Reviews Microbiology.

[38]  R. Sutter,et al.  Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. , 2014, The Journal of infectious diseases.

[39]  M. Pallansch,et al.  Vaccine-derived polioviruses and the endgame strategy for global polio eradication. , 2005, Annual review of microbiology.

[40]  Linda J S Allen,et al.  Probability of a Disease Outbreak in Stochastic Multipatch Epidemic Models , 2013, Bulletin of mathematical biology.

[41]  Stewart T. Chang,et al.  Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria , 2015, Journal of Virology.

[42]  R. Sutter,et al.  Outbreaks of paralytic poliomyelitis, 1976-1995. , 1997, The Journal of infectious diseases.

[43]  M. L. Yakovenko,et al.  A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus , 2016, Journal of Virology.

[44]  M. Pallansch,et al.  Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine‐Derived Polioviruses (cVDPVs) , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[45]  G. Dick,et al.  Vaccination Against Poliomyelitis with Live Virus Vaccines—6* , 1961, British medical journal.

[46]  T. Chin,et al.  Immunity induced by inactivated poliovirus vaccine and excretion of virus. , 1984, Reviews of infectious diseases.

[47]  N. Grassly,et al.  Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge , 2012, PLoS pathogens.

[48]  P. Strebel,et al.  Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992-1994. , 1997, The Journal of infectious diseases.

[49]  J. Meredith,et al.  Rational Design of Genetically Stable, Live-Attenuated Poliovirus Vaccines of All Three Serotypes: Relevance to Poliomyelitis Eradication , 2006, Journal of Virology.

[50]  N. Grassly,et al.  An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia , 2017, BMC Infectious Diseases.

[51]  D. Heymann,et al.  A global call for new polio vaccines , 2005, Nature.

[52]  Joel C Miller,et al.  Model hierarchies in edge-based compartmental modeling for infectious disease spread , 2013, Journal of mathematical biology.

[53]  A. V. van Loon,et al.  Poliomyelitis in the Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992 , 1995, Epidemiology and Infection.

[54]  I. Dömök,et al.  Virus Excretion after Mass Vaccination with Attenuated Polioviruses in Hungary , 1961, British medical journal.

[55]  N. Grassly,et al.  Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. , 2009, The Journal of infectious diseases.

[56]  R. Price,et al.  Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens , 2015, BMC Infectious Diseases.

[57]  N. Grassly,et al.  Asymptomatic wild-type poliovirus infection in India among children with previous oral poliovirus vaccination. , 2010, The Journal of infectious diseases.

[58]  W. J. Liu,et al.  Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin). , 1986, Bulletin of the World Health Organization.

[59]  F. de Fraipont,et al.  Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on vero cells or on primary monkey kidney cells , 1997, Journal of medical virology.

[60]  Karima R. Nigmatulina,et al.  A quantitative survey of the literature on poliovirus infection and immunity. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[61]  Y. Manor,et al.  Laboratory challenges in response to silent introduction and sustained transmission of wild poliovirus type 1 in Israel during 2013. , 2014, The Journal of infectious diseases.

[62]  C Kelly,et al.  BULLETIN EUROPÉEN SUR LES MALADIES TRANSMISSIBLES / EUROPEAN COMMUNICABLE DISEASE BULLETIN , 2003 .

[63]  F. Braka,et al.  Continued Endemic Wild Poliovirus Transmission in Security-Compromised Areas — Nigeria, 2016 , 2017, MMWR. Morbidity and mortality weekly report.

[64]  Kimberly M Thompson,et al.  Modeling Poliovirus Risks and the Legacy of Polio Eradication , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[65]  M. Pallansch,et al.  Review and Assessment of Poliovirus Immunity and Transmission: Synthesis of Knowledge Gaps and Identification of Research Needs , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[66]  Thomas D. Snyder,et al.  120 Years of American Education: A Statistical Portrait. , 1993 .

[67]  K. Thompson,et al.  Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. , 2014, The Journal of infectious diseases.

[68]  L. Hampton,et al.  Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. , 2016, MMWR. Morbidity and mortality weekly report.

[69]  T. Kimman,et al.  Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. , 1999, Journal of immunology.

[70]  V. Vashishtha,et al.  Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status , 2013, The Indian journal of medical research.

[71]  M. Pallansch,et al.  Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. , 1997, The Journal of infectious diseases.

[72]  D. Kromhout,et al.  Circulation of poliovirus during the poliomyelitis outbreak in The Netherlands in 1992-1993. , 1996, American journal of epidemiology.

[73]  T. Pollock,et al.  Vaccination of Adults with a British Oral Poliomyelitis Vaccine Prepared from Sabin Strains , 1961, British medical journal.

[74]  K. Thompson,et al.  Modeling the dynamics of oral poliovirus vaccine cessation. , 2014, The Journal of infectious diseases.

[75]  M. Mulders,et al.  Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93 , 1994, The Lancet.

[76]  Qi Chen,et al.  Multiple Independent Emergences of Type 2 Vaccine-Derived Polioviruses during a Large Outbreak in Northern Nigeria , 2013, Journal of Virology.

[77]  D. Purdie,et al.  Immunoglobulins in saliva of preterm and full-term infants. , 2003, Oral microbiology and immunology.

[78]  R. Pebody Polio vaccination in Europe: the shift from OPV to IPV use , 2004 .

[79]  W A Furumoto,et al.  A mathematical model for the infectivity-dilution curve of tobacco mosaic virus: theoretical considerations. , 1967, Virology.

[80]  D. S. Dane,et al.  Vaccination Against Poliomyelitis with Live Virus Vaccines—7 , 1961, British medical journal.

[81]  M. Pallansch,et al.  Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. , 2015, The Journal of infectious diseases.

[82]  Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011. , 2011, MMWR. Morbidity and mortality weekly report.

[83]  Joel C. Miller,et al.  Epidemic Percolation Networks, Epidemic Outcomes, and Interventions , 2011, Interdisciplinary perspectives on infectious diseases.

[84]  I. Onorato,et al.  Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. , 1991, The Journal of infectious diseases.

[85]  J. Schijven,et al.  Risk assessment, risk management and risk-based monitoring following a reported accidental release of poliovirus in Belgium, September to November 2014. , 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[86]  Dong Dx,et al.  Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin). , 1988 .

[87]  S. Plotkin,et al.  27 – Poliovirus vaccine—inactivated , 2013 .

[88]  R. D. Tebbens,et al.  Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[89]  J. Dushoff,et al.  The effects of population heterogeneity on disease invasion. , 1995, Mathematical biosciences.

[90]  M. Chumakov Some results of the work on mass immunization in the Soviet Union with live poliovirus vaccine prepared from Sabin strains. , 1961, Bulletin of the World Health Organization.

[91]  R. Mikolajczyk,et al.  Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases , 2008, PLoS medicine.

[92]  M. L. Yakovenko,et al.  Spread of Vaccine-Derived Poliovirus from a Paralytic Case in an Immunodeficient Child: an Insight into the Natural Evolution of Oral Polio Vaccine , 2005, Journal of Virology.

[93]  A. Sabin Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. , 1985, The Journal of infectious diseases.

[94]  A. Paul,et al.  Chemical Synthesis of Poliovirus cDNA: Generation of Infectious Virus in the Absence of Natural Template , 2002, Science.

[95]  Enrique Beldarraín Poliomyelitis and its elimination in Cuba: an historical overview. , 2013, MEDICC review.

[96]  S. Self,et al.  Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. , 2015, The Lancet. Infectious diseases.

[97]  A. Sabin,et al.  Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. , 1960 .

[98]  Chumakov Mp Some results of the work on mass immunization in the Soviet Union with live poliovirus vaccine prepared from Sabin strains. , 1961 .

[99]  P. Wright,et al.  Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. , 1991, Reviews of infectious diseases.

[100]  W. Weldon,et al.  The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. , 2015, Vaccine.

[101]  Walter A Orenstein,et al.  Polio vaccination: past, present and future. , 2015, Future microbiology.

[102]  R. Sutter,et al.  Poliovirus vaccine-live , 2008 .

[103]  Michael Famulare,et al.  The risk of type 2 oral polio vaccine use in post-cessation outbreak response , 2017, BMC Medicine.

[104]  F. Shuaib,et al.  Environmental isolation of circulating vaccine-derived poliovirus after interruption of wild poliovirus transmission, Nigeria, 2016. , 2016, Releve epidemiologique hebdomadaire.

[105]  Y. Manor,et al.  Molecular epidemiology of silent introduction and sustained transmission of wild poliovirus type 1, Israel, 2013. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[106]  Z. Grossman,et al.  Resolution of the Pathways of Poliovirus Type 1 Transmission during an Outbreak , 2000, Journal of Clinical Microbiology.

[107]  R. Sutter,et al.  Progress Toward Containment of Poliovirus Type 2 — Worldwide, 2017 , 2017, MMWR. Morbidity and mortality weekly report.

[108]  P E Fine,et al.  Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. , 1999, American journal of epidemiology.

[109]  K. Thompson,et al.  Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use , 2016, BMC Infectious Diseases.

[110]  M. Pallansch,et al.  Vaccine policy changes and epidemiology of poliomyelitis in the United States. , 2004, JAMA.

[111]  R. Sutter,et al.  Mass vaccination campaigns for polio eradication: an essential strategy for success. , 2006, Current topics in microbiology and immunology.

[112]  E. Opton,et al.  Immunization of preschool children with oral poliovirus vaccine (Sabin). , 1961, JAMA.

[113]  E. Hossny,et al.  Monovalent type 1 oral poliovirus vaccine in newborns. , 2008, The New England journal of medicine.

[114]  Cynthia B. Snider,et al.  Oral polio vaccine response in breast fed infants with malnutrition and diarrhea. , 2014, Vaccine.

[115]  F. Shuaib,et al.  Environmental Isolation of Circulating Vaccine-Derived Poliovirus After Interruption of Wild Poliovirus Transmission - Nigeria, 2016. , 2016, MMWR. Morbidity and mortality weekly report.

[116]  S. Self,et al.  Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial , 2016, The Lancet.

[117]  Miguel A. Galindo,et al.  Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba , 2007 .

[118]  Volume Forty Seven HEALTH AND DEMOGRAPHIC SURVEILLANCE SYSTEM - MATLAB , 2015 .

[119]  J. Fox,et al.  Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. , 1957, American journal of hygiene.

[120]  H. Larson,et al.  Listening to the rumours: What the northern Nigeria polio vaccine boycott can tell us ten years on , 2013, Global public health.

[121]  Joel C. Miller,et al.  A Note on the Derivation of Epidemic Final Sizes , 2012, Bulletin of mathematical biology.

[122]  G. Kang,et al.  Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial , 2014, The Lancet.

[123]  M. Pallansch,et al.  Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine‐Related Polioviruses , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[124]  T. Chin,et al.  Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. , 1962, American journal of hygiene.

[125]  Continued endemic wild poliovirus transmission in security-compromised areas – Nigeria, 2016. , 2017, Releve epidemiologique hebdomadaire.

[126]  Christophe Fraser,et al.  New Strategies for the Elimination of Polio from India , 2006, Science.

[127]  P. Rohani,et al.  Modeling Infectious Diseases , 2020, Strad Research.

[128]  Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003. , 2003, The Indian journal of medical research.

[129]  Y. Manor,et al.  Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel , 2016, BMC Medicine.

[130]  S. Matsui,et al.  Host and Viral Factors Affecting the Decreased Immunogenicity of Sabin Type 3 Vaccine after Administration of Trivalent Oral Polio Vaccine to Rural Mayan Children , 1997, The Journal of infectious diseases.

[131]  J. P. Davis,et al.  Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. , 2009, The Journal of infectious diseases.

[132]  A. V. van Loon,et al.  Poliovirus circulation among schoolchildren during the early phase of the 1992-1993 poliomyelitis outbreak in The Netherlands. , 2001, The Journal of infectious diseases.

[133]  M. J. Uddin,et al.  Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study , 2017, The Lancet. Infectious diseases.

[134]  O. Diop,et al.  Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 — Worldwide, 2016–2017 , 2017, MMWR. Morbidity and mortality weekly report.

[135]  W. P. Glezen,et al.  Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. , 1966, American journal of epidemiology.

[136]  Illiam,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[137]  Chris Wolff,et al.  Containment of Polioviruses After Eradication and OPV Cessation: Characterizing Risks to Improve Management , 2006, Risk analysis : an official publication of the Society for Risk Analysis.

[138]  T. Kimman,et al.  Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. , 2005, The Journal of infectious diseases.

[139]  J. Melnick,et al.  Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. , 1967, American journal of epidemiology.